Product
AZD5863
1 clinical trial
4 indications
Indication
Stomach CancerIndication
Gastroesophageal junction cancerIndication
Pancreatic Ductal AdenocarcinomaIndication
Esophageal adenocarcinomaClinical trial
A Phase I/II Open-label Dose Escalation and Dose Expansion Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of AZD5863, a T Cell-engaging Bispecific Antibody That Targets Claudin 18.2 (CLDN18.2) and CD3 in Adult Participants With Advanced or Metastatic Solid TumorsStatus: Recruiting, Estimated PCD: 2026-12-11